Effect of dantrolene in duchenne muscular dystrophy

Tulio Bertorini, Genaro M.A. Palmieri, Judy Griffin, Masanori Igarashi, Abbie Hinton, James G. Karas

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

We have demonstrated that maneuvers capable of reducing Ca influx into cells have beneficial effects in dystrophic hamsters and Duchenne muscular dystrophy. Since dantrolene inhibits Ca release from the sarcoplasmic reticulum, its effects on DMD was studied in 7 patients of 6 to 13 years of age (mean 10.8 years). Patients were studied for 4 years with tri‐monthly evaluations of manual muscle testing (MMT), functional activity, and serum CK and aldolase. During the first 2‐year period, no medicines were given and served as control. In the second 2‐year period, dantfblene 8 mg/kg/d was administered. No side effects were observed. In 1 patient, mild, weakness occurred that disappeared when the dose was reduced to 6 mg/kg/d. The 95% confidence limit for the difference in slopes of regression lines from tri‐monthly MMT was asymmetric in favor of dantrolerte in 5 of 7 patients. Serum CK did not differ between the first and second year of the control and treatment periods, respectively. However, it fell significantly from the second year of control to the first year of treatment (P = 0.003). The fall during the first year of treatment was significantly greater (P <0.01) than in age‐matched natural history controls during the same length of observation. There was a 3‐fold reduction in CK when the pooled values of the first and second year control vs. treatment periods were analyzed. No changes were observed in functional activity and serum aidolase. The data suggest that dantrolene reduces serum CK in DMD associated with a lessening trend in MMT deterioration.

Original languageEnglish (US)
Pages (from-to)503-507
Number of pages5
JournalMuscle & nerve
Volume14
Issue number6
DOIs
StatePublished - Jan 1 1991

Fingerprint

Dantrolene
Duchenne Muscular Dystrophy
Serum
Muscles
Fructose-Bisphosphate Aldolase
Sarcoplasmic Reticulum
Therapeutics
Natural History
Cricetinae
Observation

All Science Journal Classification (ASJC) codes

  • Physiology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)

Cite this

Bertorini, T., Palmieri, G. M. A., Griffin, J., Igarashi, M., Hinton, A., & Karas, J. G. (1991). Effect of dantrolene in duchenne muscular dystrophy. Muscle & nerve, 14(6), 503-507. https://doi.org/10.1002/mus.880140603

Effect of dantrolene in duchenne muscular dystrophy. / Bertorini, Tulio; Palmieri, Genaro M.A.; Griffin, Judy; Igarashi, Masanori; Hinton, Abbie; Karas, James G.

In: Muscle & nerve, Vol. 14, No. 6, 01.01.1991, p. 503-507.

Research output: Contribution to journalArticle

Bertorini, T, Palmieri, GMA, Griffin, J, Igarashi, M, Hinton, A & Karas, JG 1991, 'Effect of dantrolene in duchenne muscular dystrophy', Muscle & nerve, vol. 14, no. 6, pp. 503-507. https://doi.org/10.1002/mus.880140603
Bertorini T, Palmieri GMA, Griffin J, Igarashi M, Hinton A, Karas JG. Effect of dantrolene in duchenne muscular dystrophy. Muscle & nerve. 1991 Jan 1;14(6):503-507. https://doi.org/10.1002/mus.880140603
Bertorini, Tulio ; Palmieri, Genaro M.A. ; Griffin, Judy ; Igarashi, Masanori ; Hinton, Abbie ; Karas, James G. / Effect of dantrolene in duchenne muscular dystrophy. In: Muscle & nerve. 1991 ; Vol. 14, No. 6. pp. 503-507.
@article{9b96e9be305a4418b149e89c2c24107c,
title = "Effect of dantrolene in duchenne muscular dystrophy",
abstract = "We have demonstrated that maneuvers capable of reducing Ca influx into cells have beneficial effects in dystrophic hamsters and Duchenne muscular dystrophy. Since dantrolene inhibits Ca release from the sarcoplasmic reticulum, its effects on DMD was studied in 7 patients of 6 to 13 years of age (mean 10.8 years). Patients were studied for 4 years with tri‐monthly evaluations of manual muscle testing (MMT), functional activity, and serum CK and aldolase. During the first 2‐year period, no medicines were given and served as control. In the second 2‐year period, dantfblene 8 mg/kg/d was administered. No side effects were observed. In 1 patient, mild, weakness occurred that disappeared when the dose was reduced to 6 mg/kg/d. The 95{\%} confidence limit for the difference in slopes of regression lines from tri‐monthly MMT was asymmetric in favor of dantrolerte in 5 of 7 patients. Serum CK did not differ between the first and second year of the control and treatment periods, respectively. However, it fell significantly from the second year of control to the first year of treatment (P = 0.003). The fall during the first year of treatment was significantly greater (P <0.01) than in age‐matched natural history controls during the same length of observation. There was a 3‐fold reduction in CK when the pooled values of the first and second year control vs. treatment periods were analyzed. No changes were observed in functional activity and serum aidolase. The data suggest that dantrolene reduces serum CK in DMD associated with a lessening trend in MMT deterioration.",
author = "Tulio Bertorini and Palmieri, {Genaro M.A.} and Judy Griffin and Masanori Igarashi and Abbie Hinton and Karas, {James G.}",
year = "1991",
month = "1",
day = "1",
doi = "10.1002/mus.880140603",
language = "English (US)",
volume = "14",
pages = "503--507",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Effect of dantrolene in duchenne muscular dystrophy

AU - Bertorini, Tulio

AU - Palmieri, Genaro M.A.

AU - Griffin, Judy

AU - Igarashi, Masanori

AU - Hinton, Abbie

AU - Karas, James G.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - We have demonstrated that maneuvers capable of reducing Ca influx into cells have beneficial effects in dystrophic hamsters and Duchenne muscular dystrophy. Since dantrolene inhibits Ca release from the sarcoplasmic reticulum, its effects on DMD was studied in 7 patients of 6 to 13 years of age (mean 10.8 years). Patients were studied for 4 years with tri‐monthly evaluations of manual muscle testing (MMT), functional activity, and serum CK and aldolase. During the first 2‐year period, no medicines were given and served as control. In the second 2‐year period, dantfblene 8 mg/kg/d was administered. No side effects were observed. In 1 patient, mild, weakness occurred that disappeared when the dose was reduced to 6 mg/kg/d. The 95% confidence limit for the difference in slopes of regression lines from tri‐monthly MMT was asymmetric in favor of dantrolerte in 5 of 7 patients. Serum CK did not differ between the first and second year of the control and treatment periods, respectively. However, it fell significantly from the second year of control to the first year of treatment (P = 0.003). The fall during the first year of treatment was significantly greater (P <0.01) than in age‐matched natural history controls during the same length of observation. There was a 3‐fold reduction in CK when the pooled values of the first and second year control vs. treatment periods were analyzed. No changes were observed in functional activity and serum aidolase. The data suggest that dantrolene reduces serum CK in DMD associated with a lessening trend in MMT deterioration.

AB - We have demonstrated that maneuvers capable of reducing Ca influx into cells have beneficial effects in dystrophic hamsters and Duchenne muscular dystrophy. Since dantrolene inhibits Ca release from the sarcoplasmic reticulum, its effects on DMD was studied in 7 patients of 6 to 13 years of age (mean 10.8 years). Patients were studied for 4 years with tri‐monthly evaluations of manual muscle testing (MMT), functional activity, and serum CK and aldolase. During the first 2‐year period, no medicines were given and served as control. In the second 2‐year period, dantfblene 8 mg/kg/d was administered. No side effects were observed. In 1 patient, mild, weakness occurred that disappeared when the dose was reduced to 6 mg/kg/d. The 95% confidence limit for the difference in slopes of regression lines from tri‐monthly MMT was asymmetric in favor of dantrolerte in 5 of 7 patients. Serum CK did not differ between the first and second year of the control and treatment periods, respectively. However, it fell significantly from the second year of control to the first year of treatment (P = 0.003). The fall during the first year of treatment was significantly greater (P <0.01) than in age‐matched natural history controls during the same length of observation. There was a 3‐fold reduction in CK when the pooled values of the first and second year control vs. treatment periods were analyzed. No changes were observed in functional activity and serum aidolase. The data suggest that dantrolene reduces serum CK in DMD associated with a lessening trend in MMT deterioration.

UR - http://www.scopus.com/inward/record.url?scp=0025825220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025825220&partnerID=8YFLogxK

U2 - 10.1002/mus.880140603

DO - 10.1002/mus.880140603

M3 - Article

VL - 14

SP - 503

EP - 507

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 6

ER -